BioAffinity Technologies Forms OncoSelect Therapeutics

BioAffinity Technologies has formed OncoSelect Therapeutics, a subsidiary which will focus on leveraging BioAffinity’s porphyrin-based diagnostic technology.

The new unit will create therapeutics that will target a diverse range of cancers for precision treatment, according to the company.

“OncoSelect Therapeutics will be an important part of fulfilling BioAffinity Technologies’ mission to provide superior products to diagnose, monitor and effectively treat cancer,” said company CEO Maria Zannes.